SOURCE: CLX Medical, Inc.

June 27, 2008 10:08 ET

CLX Medical, Inc. Releases June 2008 Issue of Investor Newsletter Reviewing Current Status of Validation Study for Chlamydia Test and Proposed Acquisition of Additional Medical Diagnostic Testing Product

MURRIETA, CA--(Marketwire - June 27, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today issued the June 2008 edition of its investor newsletter, which reviews the current status of the validation study for Zonda Incorporated's rapid point of care test for chlamydia and the anticipate acquisition of an additional rapid diagnostic test for the medical market.

A PDF version of the June newsletter can be viewed on the company's corporate website at http://www.clxinvestments.com/newsletters.php.

The feature newsletter article brings shareholders up to date on the current progress of the validation study, which is designed to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product. CLX holds a majority interest in Zonda, whose tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms and are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets.

CLX was recently informed that the validation study will take longer to complete than originally planned. In order for the study to proceed, adequate growth of chlamydia cells must be achieved. While the company does not have a revised estimate of completion for the study, management does expect that it will be within a few weeks or, at best, several days.

Another newsletter article details the ongoing due diligence for the acquisition of a rapid diagnostic device for the medical market. The company does expect that its current due diligence and planning will result in a definitive agreement for the acquisition. Once CLX has reached a mutually agreed upon point in its due diligence process, it will announce the name of the device and the market that it serves.

In addressing these two topics in her greeting to shareholders contained in the newsletter, CLX CEO Vera Leonard wrote, "The coming weeks and months are shaping up to be a potentially exciting time for CLX Medical, and we look forward to reporting additional progress in each of these areas as soon as possible."

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc., which has developed rapid point of care tests for medical and non-medical markets, and CLX recently announced a letter of intent to acquire another rapid diagnostic device for the medical market. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications, Inc.
    A. Beyer
    951-677-8073
    Email Contact